Cat. No.: HY-N1373

Sophoridine

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Sophoridine is a quinolizidine alkaloid isolated from Leguminous plant Sophora flavescens. Sophoridine induces apoptosis. Sophoridine has the potential to be a novel, potent and selective antitumor agent candidate for pancreatic cancer with well-tolerated toxicity.

For research use only. We do not sell to patients.

Purity: 99.66%
CAS No.: 6882-68-4
Formula: C₁₅H₂₄N₂O
Molecular Weight:248.37

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Sophoridine Chemical Structure

CAS No.: 6882-68-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>80 μM Compound: 1	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 26865176]
A549	IC₅₀	5836 μM Compound: Sophoridine	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30025344]
CNE-2	IC₅₀	5379 μM Compound: Sophoridine	Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30025344]
HeLa	IC₅₀	4332 μM Compound: Sophoridine	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30007563]
HepG2	IC₅₀	>20 μg/mL Compound: 1	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
HepG2	IC₅₀	>80 μM Compound: 1	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25408835]
HepG2	IC₅₀	1160 μg/mL Compound: Sophoridine	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 26299348]
HepG2	IC₅₀	4509 μM Compound: Sophoridine	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30007563]
HepG2	IC₅₀	4670 μM Compound: Sophoridine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30025344]
HepG2	IC₅₀	4670 μM Compound: Sophoridine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30125725]
HepG2	IC₅₀	4670 μM Compound: Sophoridine	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamarBlue assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamarBlue assay	[PMID: 38107170]
KB	IC₅₀	>80 μM Compound: 1	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 26865176]
MCF7	IC₅₀	>80 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 26865176]
MDA-MB-231	IC₅₀	>80 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 26865176]

In Vitro

Sophoridine (0-500 μM; 48 hours) exhibits remarkable inhibition effects to the growth of human pancreatic, gastric, liver, colon, gallbladder, and prostate carcinoma cells with IC₅₀ values of about 20 μM to 200 μM^[1].
Sophoridine (0-20 μM; 48 hours) increases S phase cell population from 26.23% (control) to 38.67% in Miapaca-2 cells and from 29.56% (control) to 39.16% in PANC-1 cells, about a 1.5-fold and a 1.3-fold increase, respectively^[1].
Sophoridine (0-20 μM; 48 hours) significantly increases bad and bax levels, and decreases bcl-2 and bcl-xl levels in contrast, with a significant increase in Bax/Bcl-2 ratio^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Normal cells: IOSE144, HL-7702 and LO2, BEAS-2B, GES-1, HEK 293 T, HPDE, FHC, Human cancer cells: PANC-1, Mapaca-1, hepG2, SGC-7901, CBC-SD,SGC-996,PC-3,MKN-45,MGC-803,Hela and HCT116 cells
Concentration:

0, 3.9, 7.8, 15.5, 31, 62.5, 125, 250, 500 μM
Incubation Time:

48 hours
Result:

Exhibited the most potent cytotoxicity to cancer cells.

Cell Cycle Analysis^[1]

Cell Line:

PANC-1 cells; Miapca-2 cells
Concentration:

20 μM
Incubation Time:

48 hours
Result:

Led to accumulated population in the S phase.

Western Blot Analysis^[1]

Cell Line:

PANC-1 cells; Miapca-2 cells
Concentration:

20 μM
Incubation Time:

48 hours
Result:

Induced the activation of intrinsic apoptosis pathway.

In Vivo

Sophoridine (intraperitoneal injection; 20 or 40 mg/kg; 21 days) can inhibit the growth of xenograft pancreatic tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c homozygous (nu/nu) nude mice^[1]
Dosage:

20 or 40 mg/kg
Administration:

Intraperitoneal injection; 20 or 40 mg/kg; 21 days
Result:

Decreased xenograft pancreatic tumors mass.

Chemical Information

CAS No. 6882-68-4
Appearance Solid
Molecular Weight 248.37
Formula C₁₅H₂₄N₂O
Color Off-white to light yellow
SMILES

O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@@](CCC4)([H])CN21
Structure Classification
- Alkaloids
- Pyridine Alkaloids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All WB

Sort by:

Journal Impact Factor

Phytomedicine

Compound Kushen injection improves M1 macrophage polarisation and radiation-induced colitis by regulating Piezo1-mediated NF-κB/NLRP3 pathway. [Abstract]

2026 May:154:158055. PMID: 41818947
Pharm Biol

Sophoridine inhibits proliferation and migration by targeting PIM1 in breast cancer. [Abstract]

2025 Dec;63(1):503-523. PMID: 40708207
Int Immunopharmacol

Minimolide F alleviates inflammatory diseases by specifically targeting STING and blocking IRF3 recruitment. [Abstract]

2026 May 1:176:116468. PMID: 41819671
Front Oncol

Sophoridine Inhibits the Tumour Growth of Non-Small Lung Cancer by Inducing Macrophages M1 Polarisation via MAPK-Mediated Inflammatory Pathway. [Abstract]

2021 Feb 24:11:634851. PMID: 33718223

Sophoridine purchased from MedChemExpress. Usage Cited in: Front Oncol. 2021 Feb 24:11:634851. [Abstract]

LPS and Sophoridine (20 and 40 μg/mL) triggered the phosphorylation of JNK, ERK, and p38 MAPK in RAW264.7 and THP-1-derived macrophages. RAW264.7 and THP-1 cells are pre-treated with SP600125, and then stimulated with or without Sophoridine (20 and 40 μg/mL).
J Food Nutr Res

2021, 9(11), 591-596.
Research Square Preprint

2020 Jun.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (201.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0263 mL

20.1313 mL

40.2625 mL

5 mM

0.8053 mL

4.0263 mL

8.0525 mL

10 mM

0.4026 mL

2.0131 mL

4.0263 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (8.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (8.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.17 mg/mL (8.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xu Z, et al. Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells. J Exp Clin Cancer Res. 2017 Sep 11;36(1):124. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0263 mL	20.1313 mL	40.2625 mL	100.6563 mL
	5 mM	0.8053 mL	4.0263 mL	8.0525 mL	20.1313 mL
	10 mM	0.4026 mL	2.0131 mL	4.0263 mL	10.0656 mL
	15 mM	0.2684 mL	1.3421 mL	2.6842 mL	6.7104 mL
	20 mM	0.2013 mL	1.0066 mL	2.0131 mL	5.0328 mL
	25 mM	0.1611 mL	0.8053 mL	1.6105 mL	4.0263 mL
	30 mM	0.1342 mL	0.6710 mL	1.3421 mL	3.3552 mL
	40 mM	0.1007 mL	0.5033 mL	1.0066 mL	2.5164 mL
	50 mM	0.0805 mL	0.4026 mL	0.8053 mL	2.0131 mL
	60 mM	0.0671 mL	0.3355 mL	0.6710 mL	1.6776 mL
	80 mM	0.0503 mL	0.2516 mL	0.5033 mL	1.2582 mL
	100 mM	0.0403 mL	0.2013 mL	0.4026 mL	1.0066 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sophoridine

Apoptosis Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Off-patent Drug Library

Highly Selective Activators Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Cancer Approved Drug Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

3D Diverse Fragment Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Sophoridine

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Sophoridine Related Classifications

Cat. No.: HY-N1373